The refreshed mission—to empower partners to advance treatments that promote global health and well-being—marks a deepened focus on transforming patient care through innovative drug development. With patient-centered care at its core, TFS reinforces its role as a CRO that not only supports the pharmaceutical industry but drives meaningful impact on global health.

TFS specializes in key therapeutic areas, including dermatology, internal medicine, neuroscience, oncology, and ophthalmology, making it a standout partner among global mid-sized CROs. These focus areas enable TFS to address some of the most pressing health challenges while delivering tailored clinical research solutions for its partners.

TFS’s new mission was shaped by a diverse focus group, who helped redefine the company’s identity, emphasizing sustainability, diversity, and the global impact of clinical trials. This inclusive approach ensures that TFS is aligned with the evolving needs of its partners while maintaining a patient-centered and people-first philosophy.

“Our new mission and tagline are more than a rebranding exercise; they define our purpose,” said Patrik Darsund, Chief People Officer at TFS. “We are committed to making a lasting difference by empowering our partners and enriching the lives of patients through every trial, every innovation, and every collaboration.”

For over two decades, TFS has built a reputation for delivering clinical research excellence, and this new mission reinforces its ongoing evolution. By combining the global reach of a large CRO with the flexibility and responsiveness of a mid-sized organization, TFS continues to support its clients and partners in navigating the complexities of the healthcare landscape.

“TFS is at a pivotal moment in its evolution,” said Dr. Bassem Saleh, CEO of TFS HealthScience. “We are committed to staying true to our core values while evolving to meet tomorrow’s challenges. By empowering our clients and keeping patients at the center of what we do, we continue to serve as a trusted partner.”

About TFS HealthScience

TFS HealthScience is a full-service, global Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With over 800 professionals operating across 40 countries, TFS delivers tailored clinical research services in specialized therapeutic areas, including dermatology, internal medicine, neuroscience, oncology, and ophthalmology. Dedicated to empowering partners and enriching lives, TFS offers flexible solutions that combine global reach with the agility and responsiveness of a mid-sized CRO.

For more information, visit www.tfscro.com.

The post TFS HealthScience Unveils Mission to Empower Partners and Enrich Lives Worldwide appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

The partnership ensures seamless delivery of these important studies with cutting-edge AI-enabled technologies. Both trials will leverage RetinAI’s Discovery® platform, which offers a robust platform infrastructure for data upload, management, and imaging analysis. Discovery provides data security and facilitates real-time data sharing and collaboration on a single cloud-based platform, enabling global multicenter studies and monitoring of study progress among stakeholders.

Dr. Carlos Ciller, Chairman and CEO of Ikerian and CEO of RetinAI, expressed his enthusiasm for this collaboration: “Our work with MAXO and TFS on these significant programs underscores our commitment to advancing clinical research and clinical trials in Ophthalmology. By integrating our Discovery platform, we aim to streamline data management and facilitate operations towards better study outcomes. We are dedicated to supporting CROs and Reading Centers by providing robust, user-friendly solutions that simplify data workflows in clinical trials. This collaboration is a testament to our continuous efforts to innovate and improve operations of clinical trials with efficient, intuitive technology.”

Dr. Bassem Saleh, CEO of TFS, stated: “This partnership with RetinAI and MAXO represents a significant advancement in our mission to deliver innovative solutions to our clients. By integrating cutting-edge AI-enabled technologies, we are not only enhancing the efficiency and accuracy of our clinical trials but also paving the way for transformative drug development. We are excited about the potential impact this collaboration will have on improving patient outcomes and advancing ophthalmology research.”

About RetinAI Inc. US and Ikerian AG

Established in 2017, RetinAI (Part of Ikerian AG), develops software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision.

Focused on the ophthalmology and optometry market, RetinAI builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare. RetinAI’s international team leverages its clinical, technical, and scientific expertise to foster the transition from reactive to preventive medicine for severe eye diseases.

Follow RetinAI on LinkedIn
Follow Ikerian on Linkedin

About RetinAI Discovery®

RetinAI Discovery® (‘Discovery’) is a software platform to enable the right decisions sooner based on evidence, AI-derived insights, automation & data. Discovery is a modular and certified (FDA – 510(K) / CE – MDR) medical image & data platform that digests data, works via the web browser in the cloud, enables precision analysis with proprietary AI models and transfer of medical data linked to the patient, connecting devices, data sources & decisions in a seamless and secure manner. Discovery is the workbench for healthcare professionals throughout the entire journey of the disease, facilitating decisions for better patient care.

About TFS HealthScience

TFS HealthScience is a full-service, global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working towards a healthier future. Bringing together nearly 800 professionals, TFS delivers tailored clinical research services in more than 40 countries with flexible clinical development and strategic resourcing solutions across key therapeutic areas, including Dermatology, Immunology & Inflammatory Diseases, Internal Medicine, Neuroscience, Oncology & Hematology, and Ophthalmology.

Detailed information about TFS and its business offerings can be obtained through www.tfscro.com.

The post RetinAI Partners with MAXO to Advance Clinical Studies in Dry Eye Disease appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

 O’Brien brings nearly 40 years of clinical research experience to this critical role. Her extensive career includes leadership roles across the CRO, pharmaceutical, and academic sectors, with more than half of her professional journey focused on oncology and rare diseases. In past roles, she served in positions such as Vice President of Operations, Executive Director of Strategy, and Head of Project Management. Throughout her career, she has focused on her strategic vision and deep commitment to improving the patient journey, especially for those in need of life-altering and life-saving therapies. 

 In her new role, O’Brien will oversee all oncology and rare disease programs at TFS, ensuring that projects are delivered with the highest standards of quality and operational excellence. Her expertise in patient recruitment, retention, and study visit design will be instrumental in guiding her team and supporting sponsors, driving superior outcomes in some of the most challenging therapeutic areas. 

 “Kris’s depth of experience and passion for patient-centric clinical trials make her an exceptional leader for our Oncology & Rare Diseases teams, partners, and clients,” said Bassem Saleh, CEO of TFS. “Her proven track record of operational excellence and her dedication to improving patient care align perfectly with TFS’s mission and values. We are confident that Kris will make a significant impact on our work and the clients and patients we serve.” 

 Reflecting on her new role, O’Brien shared, “I am honored to join TFS, an organization that shares my commitment to advancing clinical research and improving the lives of patients around the world. I am eager to collaborate with this talented team to drive innovation and deliver high-quality results for our clients and their patients.” 

 O’Brien’s appointment is expected to significantly benefit TFS’s clients in the oncology and rare diseases therapeutic areas by enhancing service quality, communication across channels, and collaboration with clients and clinics. With O’Brien’s leadership, TFS expects to execute more efficient, higher-quality clinical trials, ensuring a more patient-centric approach that aligns with the needs of both clients and patients. Her experience will be instrumental in bridging any gaps within these areas of the organization, fostering excellence across the board and reinforcing TFS’s commitment to delivering exceptional outcomes in these critical therapeutic domains. 

 About TFS HealthScience 

TFS HealthScience is a full-service, global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working towards a healthier future. Bringing together nearly 800+ professionals, TFS delivers tailored clinical research services in more than 40 countries with flexible clinical development and strategic resourcing solutions across key therapeutic areas, including Dermatology, Neuroscience, Oncology, and Ophthalmology. 

Detailed information about TFS and its business offerings can be obtained through www.tfscro.com. 

The post TFS HealthScience Appoints Kris O’Brien as Vice President, Head of Oncology & Rare Diseases appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

Hornagold brings over 25 years of clinical research experience, having held senior management positions at prominent CROs, including Cmed Clinical Services and Aixial Group. Most recently, she served as Head of Project Management at Aixial Group, where she was instrumental in driving process efficiencies and ensuring high-quality outcomes for customers.

In her new role, Hornagold will oversee TFS’s clinical development services, including biometrics, contract management, drug safety and pharmacovigilance, medical and site monitoring, medical writing, quality, study start-up, and trial master file delivery. Her leadership will focus on enhancing client delivery through innovative, patient-centric practices and streamlined processes. With her guidance, TFS expects to deliver faster, more reliable business processes and organizational practices, resulting in enhanced project outcomes and upholding the highest standards of compliance and quality.

“Victoria’s extensive experience and strategic approach to clinical development services will be invaluable as we continue to grow and enhance our services for our customers,” said Bassem Saleh, CEO of TFS. “Her commitment to operational excellence and collaborative leadership aligns perfectly with our goals and mission. As a welcome addition to our executive management team, she brings new energy and insight that will further our success. We are excited to welcome her to our team and look forward to the positive impact she will have on our customers’ success and patient care.”

“Having spoken with TFS employees from diverse teams over the last months, I have been impressed by the openness, commitment, and positivity,” expressed Hornagold. “TFS has a clear identity and vision for the future, and I am very proud to be joining this dynamic team.”

Hornagold’s appointment is set to significantly benefit TFS’s customers and partners by enhancing service quality and collaboration and create a more efficient and motivated workforce by fostering innovation and continuous improvement. Hornagold’s addition to the team further underscores TFS’s ongoing dedication to operational excellence and patient-centric innovation, benefiting customers, patients, and employees alike.

About TFS HealthScience

TFS HealthScience is a full-service, global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working towards a healthier future. Bringing together nearly 800+ professionals, TFS delivers tailored clinical research services in more than 40 countries with flexible clinical development and strategic resourcing solutions across key therapeutic areas, including Dermatology, Immunology & Inflammatory Diseases, Internal Medicine, Neuroscience, Oncology & Hematology, and Ophthalmology.

Detailed information about TFS and its business offerings can be obtained through www.tfscro.com.

The post TFS HealthScience Appoints Victoria Hornagold as New VP of Clinical Development Services (CDS) appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

 Aligned with their strong dedication to Environmental, Social, and Governance (ESG) principles, TFS demonstrates advanced management systems for ethics, labor and human rights, and environmental issues. By incorporating the EcoVadis rating into their ESG strategy, they continue to enhance their sustainability performance in a comprehensive manner.  

The organization’s 2023 Sustainability Report details substantial advancements in environmental care, social responsibility, and sustainable business operations.  

You can access the full report here. 

 Earlier this year, TFS also reported an improvement of its Carbon Disclosure Project (CDP) scoring from ‘D’ to ‘C,’ reflecting enhanced initiatives in managing environmental impact. The CDP, a global nonprofit, operates the world’s leading platform for environmental information disclosure. Additionally, TFS has committed to setting science-based targets with the Science Based Targets initiative (SBTi), further demonstrating its ambition to reduce its carbon footprint and support global climate goals.  

 “Receiving the Silver Rating from EcoVadis for the fifth year in a row validates our ongoing commitment to creating an ethical and sustainable business,” said Patrik Darsund, Chief People Officer at TFS. “We are proud of the progress we’ve made and continue to strive for significant contributions to the health sciences field and beyond.” 

 This achievement highlights TFS’s reliability and ethical practices, which are vital for building trust with its partners and clients. TFS’s sustainability efforts reflect the organization’s strong focus on transparency and accountability, assuring partners and clients of its integrity. 

 Learn more about how TFS HealthScience is paving the way for a sustainable future in clinical research. 

 About TFS HealthScience 

TFS HealthScience is a full-service, global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working towards a healthier future. Bringing together nearly 800+ professionals, TFS delivers tailored clinical research services in more than 40 countries with flexible clinical development and strategic resourcing solutions across key therapeutic areas, including Dermatology, Immunology & Inflammatory Diseases, Internal Medicine, Neuroscience, Oncology & Hematology, and Ophthalmology.  

Detailed information about TFS and its business offerings can be obtained through www.tfscro.com 

The post TFS HealthScience Earns Fifth Consecutive Silver Rating from EcoVadis for Sustainability Excellence appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

The post Test appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

Read the full report here.

“Our commitment to sustainability is not just a goal; it’s a fundamental principle that guides our actions and decisions,” remarks Patrik Darsund, Chief People Officer at TFS. “We are proud of the progress we’ve made and remain committed to advancing sustainability in everything we do.”

TFS’s Sustainability Report 2023 highlights significant advancements across various fronts:

Environmental (E):

• Enhanced Carbon Management: Adoption of advanced CO2 emission tracking tools demonstrates proactive environmental stewardship, aligning operations with regulatory standards and emphasizing transparency in environmental impact.
• Sustainable Operations Initiatives: Implementation of a global travel booking platform and investment in renewable energy sources and eco-friendly procurement practices minimize TFS’ environmental footprint and support climate action.
• Commitment to Science-Based Targets: Initiating the Science-Based Targets initiative (SBTi) reflects a strategic approach to reducing carbon emissions, aligning with global efforts to combat climate change.

Social (S):

• Diversity and Inclusion: A workforce composition reflecting a strong commitment to gender diversity at all levels of the organization fosters an inclusive workplace culture that values and respects diversity.
• Employee Engagement and Development: High engagement scores and extensive training initiatives illustrate TFS’s investment in employees’ professional growth and well-being, emphasizing the importance of people in achieving the company’s mission.
• Community Engagement and Impact: Strategic partnerships and community engagement initiatives demonstrates a commitment to broader social issues, including health disparities and access to clinical trials, driving positive societal change.

Governance (G):

• Ethical Conduct and Compliance: Reinforced ethical business practices through policies and training programs and a zero-tolerance stance towards corruption, underscores TFS’s commitment to integrity, transparency, and accountability in all its operations.
• Strategic Leadership and Oversight: The Executive Committee’s active involvement in sustainability commitments and adoption of global ESG reporting standards demonstrate effective steering towards sustainability goals.
• Risk Management and Data Protection: Holistic risk management, including data privacy and security, showcases a commitment to safeguarding stakeholders’ interests and ensuring service integrity and reliability.

This report underscores the company’s dedication to sustainability and exemplifies the progress made, reinforcing TFS’ position as a frontrunner in the pursuit of environmentally conscious and socially responsible business practices.

Dr. Bassem Saleh, Chief Executive Officer at TFS, further emphasizes, “Our achievements in earning the EcoVadis Silver rating for the fourth consecutive year and improving our Carbon Disclosure Project score underscore our unwavering dedication to environmental stewardship and transparency. Moreover, our commitment to the Science-based Targets Initiative reflects our proactive stance in addressing climate change through concrete, science-driven strategies. These milestones not only validate our efforts but also inspire us to continuously raise the bar in sustainability excellence.”

For more information on TFS HealthScience’s Sustainability Report 2023 and its commitment to sustainability, please visit the CRO’s site here.

About TFS HealthScience

TFS HealthScience is a full-service, global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working towards a healthier future. Bringing together nearly 800+ professionals, TFS delivers tailored clinical research services in more than 40 countries with flexible clinical development and strategic resourcing solutions across key therapeutic areas, including Dermatology, Immunology & Inflammatory Diseases, Internal Medicine, Neuroscience, Oncology & Hematology, and Ophthalmology.

Detailed information about TFS and its business offerings can be obtained through www.tfscro.com

The post TFS HealthScience Releases its Sustainability Report 2023 appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

With a recorded 23,000+ companies disclosing through CDP in 2023, disclosing data on environmental impact is now a business norm. TFS’s data will be added to the most comprehensive inventory of self-reported environmental data in the world – helping to drive action through greater transparency.  

Kajsa Petersson, Internal Communications, Culture and Sustainability Director at TFS, said, “We are honored to receive CDP recognition for our commitment to environmental transparency. Our dedication to disclosure stems from our commitment to delivering high-quality clinical research responsibly, fostering the long-term success of the healthcare industry – providing life-saving care to patients globally.”  

By disclosing through CDP, TFS is prepared to respond to the increasing demand for environmental transparency from financial institutions, customers, and policymakers. In its disclosure, TFS shared information on past, current, and future strategies for identifying and addressing the company’s environmental impact. 

“We believe that implementing sustainable strategies is an integral part of our business activities. Having our efforts recognized by CDP motivates us to continue on the path to a greener, healthier, more sustainable future for all,” said Patrik Darsund, Chief People Officer, at TFS.

TFS showcases its commitment to environmental sustainability by leveraging advanced, automated data collection platforms and intelligent travel emission tracking software, highlighting its proactive stance. Already engaged in setting science-based emissions targets through the Science Based Targets initiative (SBTi) for 2025, the company aims at enhancing sustainable procurement, investing in renewable energy, and optimizing energy-efficient operations. This commitment is further evidenced by its consistent Silver Rating from EcoVadis, placing it within the top 8% of 1.6 million companies in 2023, marking a notable rise from the top 15% in 2022. 

Sherry Madera, CDP’s Chief Executive Officer, stated, “With over 23,000 businesses disclosing through CDP this year, it is clear that sustainability, and the data that underpins it, is an essential part of long-term success in the business community. Disclosure works, and today we should take a short pause to celebrate the dedication to transparency and accountability shown by TFS HealthScience reporting through CDP this year. By sharing their environmental data with CDP, TFS HealthScience is continuing, an environmental journey that will contribute to keeping that future in sight.” 

The full list of companies disclosing through CDP can be accessed here: https://www.cdp.net/en/responses 

About TFS HealthScience

TFS HealthScience is a full-service, global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working towards a healthier future. Bringing together nearly 800+ professionals, TFS delivers tailored clinical research services in more than 40 countries with flexible clinical development and strategic resourcing solutions across key therapeutic areas, including Dermatology, Immunology & Inflammatory Diseases, Internal Medicine, Neuroscience, Oncology & Hematology, and Ophthalmology.  

Detailed information about TFS and its business offerings can be obtained through www.tfscro.com 

About CDP

CDP is a global non-profit that runs the world’s environmental disclosure system for companies, cities, states, and regions. Founded in 2000, CDP works with more than 740 financial institutions with over US$137 trillion in assets. They have pioneered using capital markets and corporate procurement to motivate companies to disclose their environmental impacts, reduce greenhouse gas emissions, safeguard water resources, and corporate procurement to motivate companies to disclose their environmental impacts, reduce greenhouse gas emissions, safeguard water resources, and protect forests. Over 25,000 organizations around the world disclosed data through CDP in 2023, with more than 23,000 companies – including listed companies worth two-thirds of global market capitalization – and over 1,100 cities, states, and regions. 

Fully TCFD aligned, CDP holds the largest environmental database in the world, and CDP scores are widely used to drive investment and procurement decisions towards a zero carbon, sustainable, and resilient economy. CDP is a founding member of the Science Based Targets initiative, We Mean Business Coalition, The Investor Agenda, and the Net Zero Asset Managers initiative. Visit ww.cdp.net to learn more

Media Contact  

Emma Primon 
Executive Director, Marketing & Communications
+1 (908) 331.5463
Email

The post TFS HealthScience Earns Elevated Score from Carbon Disclosure Project (CDP)  appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

The APAC region presents a promising landscape for clinical research, with a diverse patient population encompassing various ethnicities, demographics, and medical conditions. According to the Clinical Leader, the APAC CRO market is expected to grow to US$12 billion by 2025. TFS recognizes the potential to contribute significantly to advancing medical knowledge and improving patient outcomes in this vibrant and growing market. 

Dr. Bassem Saleh, Chief Executive Officer at TFS, expressed his enthusiasm for the expansion, stating, “As we extend our footprint into the APAC region, Australia emerges as a strategic focal point for establishing operations in all our business units, including Ophthalmology, Dermatology, Neurology, Oncology, and Strategic Resourcing. Australia’s expanding market aligns perfectly with our vision for growth and innovation. This expansion enables us to better integrate into the APAC region and strengthens our commitment to delivering unparalleled clinical research solutions to our global network.” 

While the company has previously offered geographical coverage through consultants and partner CROs in the region, this expansion represents a commitment to developing a dedicated operational base, expanding their site network, and patients’ access to clinical trials. Starting with Australia, TFS has plans for further growth into other countries in the APAC region, complementing existing partnerships to cater to customer needs globally. 

TFS’s expansion into the APAC region enhances the company’s partnership capabilities, offering unique advantages to sponsors and partners. This strategic move not only broadens access to diverse patient populations and cutting-edge technologies but also leverages streamlined regulatory environments for faster, more efficient trial execution. By integrating this with its commitment to cultural diversity and global collaboration, TFS underlines its role as a leading CRO partner, equipped to navigate the complexities of global clinical research with precision and cultural sensitivity. 

About TFS HealthScience  

TFS HealthScience is a full-service, global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working towards a healthier future. Bringing together nearly 800+ professionals, TFS delivers tailored clinical research services in more than 40 countries with flexible clinical development and strategic resourcing solutions across key therapeutic areas, including Dermatology, Immunology & Inflammatory Diseases, Internal Medicine, Neuroscience, Oncology & Hematology, and Ophthalmology. 

Detailed information about TFS and its business offerings can be obtained through www.tfscro.com 

Media Contact  

Emma Primon 
Executive Director, Marketing & Communications
+1 (908) 331.5463
Email

The post TFS HealthScience Unveils Asia Pacific Expansion, Elevating Patient Access and Innovation appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

CHARLOTTE, N.C. (Dec. 11, 2023) – Premier, Inc.’s PINC AI Applied Sciences (PAS) and TFS HealthScience are announcing a landmark collaboration to accelerate global clinical trials and research innovation, improve patient outcomes and reduce health disparities.  

The partnership will combine TFS’ capabilities, systems, and clinical development expertise with PAS’ AI-enabled technology and comprehensive healthcare database. The collaboration will expedite site and patient enrollment, reduce trial costs, accelerate the journey to commercialization, and ensure equitable access to groundbreaking medical solutions across diverse patient populations. 

Eighty percent of all trials face premature termination or significant delays due to recruitment challenges – and marginalized populations, including Black and Hispanic individuals, remain historically underrepresented.  

Leveraging comprehensive real-world data (RWD) and AI-enabled tools from PAS, TFS will gain enhanced capabilities to assess site suitability on a larger scale and focus on appropriate patient populations, investigator availability, therapeutic areas expertise and historical clinical trial performance metrics. This data-driven approach has already enabled PAS-supported trials to improve recruitment by 1800 percent and triple enrollment compared to baseline projections – significantly reducing enrollment periods and costs. 

“The PAS-TFS partnership will bring the advantages of high-quality RWD/RWE and the benefits of AI-enabled technology to trial sponsors, investigators and life sciences entities worldwide,” said Denise Juliano, Group Vice President of Life Sciences at Premier. “Our combined strengths will help enhance data analysis, provide trial designs that are both diverse and equitable, advance early disease detection and reduce disparities with aim to advance global health equity.” 

Dr. Bassem Saleh, Chief Executive Officer at TFS, emphasizes the global impact of the collaboration: “Technology, including AI, will help accelerate clinical research through efficient clinical trial designs, synthetic arms, and faster patient identification and recruitment. Working with PAS will open new avenues for innovative clinical trials in Europe and the U.S., benefiting biotech, pharma and medical device companies across various phases and real-world evidence studies and ensuring more inclusive and patient-centric research.”   

The PAS-TFS partnership has plans for implementation in multiple studies per year across all therapeutic areas and indications. Data-driven designs will enable sponsors to integrate decentralized approaches with an emphasis on remote health and in-home patient monitoring options using mobile apps and wearables, helping lower overall trial costs. 

This strategic collaboration is set to further enable TFS’s expansion in the U.S. and enhance PINC AI’s global influence, especially in the European market, leveraging TFS’s extensive network. By uniting their capabilities, PAS and TFS are committed to driving forward innovation in clinical research and offering efficient solutions that prioritize patient health outcomes and equity.  

About TFS HealthScience
TFS HealthScience is a global clinical Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working for a healthier future. Bringing together nearly 800 professionals, TFS delivers tailored clinical research services in more than 40 countries and supports customers with comprehensive solutions through two strong business models: Clinical Development Services (CDS), which provides full-service support at all stages of the clinical development process and Strategic Resourcing Solutions (SRS), which offers expert insourcing, targeted recruitment, and strategic workforce management solutions. 

About PINC AI Applied Sciences (PAS)
PAS is a trusted leader in accelerating healthcare improvement through services, data and scalable solutions, spanning the continuum of care and enabling sustainable innovation and rigorous research. These services and RWD are valuable resources for the pharmaceutical, device and diagnostic industries, academia, federal and national healthcare agencies, as well as hospitals and health systems. Since 2000, PAS researchers have produced more than 1,000 publications which appear in 264 scholarly, peer-reviewed journals, covering a wide variety of topics, and conduct population-based analyses of drugs, devices, treatments, disease states, epidemiology, resource utilization, healthcare economics and clinical outcomes. 

About the PINC AI Platform
PINC AI is the technology and services platform of Premier, Inc. (NASDAQ: PINC). With more than 20 years’ worth of cost, quality and operational data gleaned from 45 percent of U.S. hospital discharges, 2.7 billion hospital outpatient and clinic encounters and 177 million physician office visits, the PINC AI platform provides actionable intelligence to help improve outcomes, support improved financial performance and enable success in new, alternative payment models. PINC AI incorporates the 100 Top Hospitals ® Program that inspires hospital and health system leaders to pursue higher performance and deliver added value to their patients and communities. PINC AI offerings rely on advanced analytics to identify improvement opportunities; support award-winning Strategic Collaboratives for value-based care, maternal and infant health, workforce innovation, and health equity; and consulting services for clinical and operational design, and workflow solutions to hardwire sustainable change. The PINC AI platform is also the data engine powering Premier’s newest brands – Remitra® and Contigo Health®. With a leading network of provider organizations, the PINC AI platform accelerates ingenuity and serves as a large-scale innovation catalyst in healthcare. PINC AI offerings and capabilities can be followed on X (formerly Twitter) and LinkedIn. 

Contact: Public_Relations@premierinc.com 

The post Premier, Inc.’s PINC AI™ Applied Sciences (PAS) and TFS HealthScience Will Partner to Revolutionize Clinical Trials appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.